Loss of Appetite in Adult Patients: Effectiveness and Safety of an Appetite Stimulating Medication in an Open-Label, Investigator-Initiated Study in India
Table 3
Summary of concomitant medication (safety population).
Class medication name, n (%)
Overall (N = 50)
Acetic acid derivatives and related substances
5 (10.0)
Aceclofenac
5 (10.0)
Angiotensin II receptor blockers
6 (12.0)
Olmesartan
1 (2.0)
Telmisartan
5 (10.0)
Anilides
5 (10.0)
Paracetamol
5 (10.0)
Selective beta-blocking agents
2 (4.0)
Atenolol
2 (4.0)
Biguanides
22 (44.0)
Metformin
22 (44.0)
Combinations of penicillins, including beta-lactamase inhibitors
1 (2.0)
Amoxicillin/potassium clavulanate
1 (2.0)
Dipeptidyl peptidase 4 inhibitors
8 (16.0)
Teneligliptin
8 (16.0)
Expectorants
3 (6.0)
Guaifenesin
3 (6.0)
HMG-CoA reductase inhibitors
1 (2.0)
Atrovastatin
1 (2.0)
Insulins and analogues for injection (intermediate- or long-acting combined with fast-acting)